These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36328025)
1. Accelerating the integration of China into the global development of innovative anticancer drugs. Huang H; Wu D; Miao H; Tang Y; Liu C; Fang H; Meng X; Wang S; Zhu Q; Wang X; Du J; Yang Z; Li N; Xu B; He J Lancet Oncol; 2022 Nov; 23(11):e515-e520. PubMed ID: 36328025 [TBL] [Abstract][Full Text] [Related]
2. Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval. Huang H; Miao H; Wang J; Wu D; Lei Q; Wang S; Fang H; Tang Y; Li N; Xu B; He J J Natl Cancer Cent; 2021 Dec; 1(4):147-152. PubMed ID: 39036805 [TBL] [Abstract][Full Text] [Related]
3. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA. Wu SL; Zhang Y; Fu Y; Li J; Wang JS BMJ Open; 2022 Jul; 12(7):e061038. PubMed ID: 35863834 [TBL] [Abstract][Full Text] [Related]
4. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan]. Pflieger M; Bertram D Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054 [TBL] [Abstract][Full Text] [Related]
5. Hematology research output from Chinese authors and other countries: a 10-year survey of the literature. Zhang L; Ye X; Sun Y; Deng AM; Qian BH J Hematol Oncol; 2015 Feb; 8():8. PubMed ID: 25653049 [TBL] [Abstract][Full Text] [Related]
6. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect]. Cao H; Wang M Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):812-819. PubMed ID: 31550818 [TBL] [Abstract][Full Text] [Related]
7. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study. Pan J; Wei X; Lu H; Wu X; Li C; Hai X; Lan T; Dong Q; Yang Y; Jakovljevic M; Zhou J Lancet Reg Health West Pac; 2024 Jun; 47():101088. PubMed ID: 38774422 [TBL] [Abstract][Full Text] [Related]
8. Factors affecting fluctuations in China's aquatic product exports to Japan, the USA, South Korea, Southeast Asia, and the EU. Miao M; Liu H; Chen J Aquac Int; 2021; 29(6):2507-2533. PubMed ID: 34421231 [TBL] [Abstract][Full Text] [Related]
9. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea. Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625 [TBL] [Abstract][Full Text] [Related]
10. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise]. Ekimoto H Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236 [TBL] [Abstract][Full Text] [Related]
11. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan. Hino Y; Okada M; Hallgreen CE; De Bruin ML; Doty RE; Matsumaru N; Tsukamoto K Biol Pharm Bull; 2023 May; 46(5):700-706. PubMed ID: 36878610 [TBL] [Abstract][Full Text] [Related]
12. [Progress on clinical trials of cancer drugs in China, 2019]. Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647 [No Abstract] [Full Text] [Related]
13. Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015. Pu QH; Lyu QJ; Su HY BMJ Open; 2016 Aug; 6(8):e011623. PubMed ID: 27489154 [TBL] [Abstract][Full Text] [Related]
14. Rapid advances in research on and development of anticancer drugs in China. Yao X; Du N; Hu S; Wang L; Gao J Biosci Trends; 2019 Nov; 13(5):461-463. PubMed ID: 31511442 [TBL] [Abstract][Full Text] [Related]
15. Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea. Yang S; Lin S; Li N; Deng Y; Wang M; Xiang D; Xiang G; Wang S; Ye X; Zheng Y; Yao J; Zhai Z; Wu Y; Hu J; Kang H; Dai Z J Hematol Oncol; 2020 Nov; 13(1):146. PubMed ID: 33138852 [TBL] [Abstract][Full Text] [Related]
16. [Progress on clinical trials of cancer drugs in China, 2020]. Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488 [No Abstract] [Full Text] [Related]
17. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility. Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893 [TBL] [Abstract][Full Text] [Related]
18. Cancer burden and trends in China: A review and comparison with Japan and South Korea. Sun D; Cao M; Li H; He S; Chen W Chin J Cancer Res; 2020 Apr; 32(2):129-139. PubMed ID: 32410791 [TBL] [Abstract][Full Text] [Related]
19. A cross-country core strategy comparison in China, Japan, Singapore and South Korea during the early COVID-19 pandemic. Chen H; Shi L; Zhang Y; Wang X; Sun G Global Health; 2021 Feb; 17(1):22. PubMed ID: 33618688 [TBL] [Abstract][Full Text] [Related]
20. A comparative study of the disease burden attributable to PM Du J; Yang J; Wang L; Wu X; Cao W; Sun S Ecotoxicol Environ Saf; 2021 Feb; 209():111856. PubMed ID: 33412383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]